Table 2.
Urticaria therapies overall and by diagnostic subgroup at baseline and at study end.
| Diagnostic subgroup | CSU |
CIndU |
CSU + CIndU |
Overall |
||||
|---|---|---|---|---|---|---|---|---|
| Baseline (V1) | Study end (V9) | Baseline (V1) | Study end (V9) | Baseline (V1) | Study end (V9) | Baseline (V1) | Study end (V9) | |
| NS H1-antihistamine approved, n (%) | 716 (21.1) | 255 (14.5) | 48 (19.4) | 13 (10.3) | 222 (18.5) | 107 (15.8) | 986 (20.4) | 375 (14.7) |
| Up-dosed NS H1-antihistamine, n (%) | 866 (25.6) | 236 (13.4) | 81 (32.7) | 28 (22.2) | 289 (24.0) | 88 (13.0) | 1236 (25.5) | 352 (13.8) |
| On demand NS H1-antihistamine, n (%) | 180 (5.3) | 189 (10.8) | 18 (7.3) | 17 (13.5) | 65 (5.4) | 59 (8.7) | 263 (5.4) | 265 (10.4) |
| S H1-antihistamine, n (%) | 115 (3.4) | 49 (2.8) | 12 (4.8) | 2 (1.6) | 36 (3.0) | 17 (2.5) | 163 (3.4) | 68 (2.7) |
| Combination NS H1-antihistamine & S H1-antihistamine, n (%) | 148 (4.4) | 52 (3.0) | 10 (4.0) | 1 (0.8) | 78 (6.5) | 29 (4.3) | 236 (4.9) | 82 (3.2) |
| Omalizumaba, n (%) | 720 (21.3) | 523 (29.8) | 32 (12.9) | 34 (27.0) | 273 (22.7) | 212 (31.4) | 1025 (21.2) | 769 (30.1) |
| Montelukastb, n (%) | 180 (5.3) | 37 (2.1) | 10 (4.0) | 7 (5.6) | 85 (7.1) | 26 (3.8) | 275 (5.7) | 70 (2.7) |
| Ciclosporinec, n (%) | 34 (1.0) | 10 (0.6) | 1 (0.4) | 1 (0.8) | 13 (1.1) | 6 (0.9) | 48 (1.0) | 17 (0.7) |
| Other, n (%) | 87 (2.6) | 48 (2.7) | 9 (3.6) | 2 (1.6) | 30 (2.5) | 19 (2.8) | 126 (2.6) | 69 (2.7) |
| No treatment, n (%) | 341 (10.1) | 358 (20.4) | 27 (10.9) | 21 (16.7) | 112 (9.3) | 113 (16.7) | 480 (9.9) | 492 (19.2) |
| Total, n (%) | 3387 (100.0) | 1757 (100.0) | 248 (100.0) | 126 (100.0) | 1203 (100.0) | 676 (100.0) | 4838 (100.0) | 2559 (100.0) |
a
Treatment with omalizumab (without ciclosporine).
b
Treatment with montelukast (without ciclosporine or omalizumab).
c
Treatment with ciclosporine (without montelukast or omalizumab) n = number of patients; CIndU, chronic inducible urticaria; CSU, chronic spontaneous urticaria; NS, non-sedating; S, sedating